TISIDB

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF01388 ARID/BRIGHT DNA binding domain PF08169 RBB1NT (NUC162) domain PF11717 RNA binding activity-knot of a chromodomain
Function	Interacts with the viral protein-binding domain of the retinoblastoma protein.

> Gene Ontology [ TOP ]
Biological Process	GO:0002064 epithelial cell development GO:0002262 myeloid cell homeostasis GO:0006349 regulation of gene expression by genetic imprinting GO:0006476 protein deacetylation GO:0006479 protein methylation GO:0007283 spermatogenesis GO:0007548 sex differentiation GO:0008213 protein alkylation GO:0008406 gonad development GO:0008584 male gonad development GO:0016570 histone modification GO:0016571 histone methylation GO:0016575 histone deacetylation GO:0018022 peptidyl-lysine methylation GO:0018023 peptidyl-lysine trimethylation GO:0018205 peptidyl-lysine modification GO:0030099 myeloid cell differentiation GO:0030218 erythrocyte differentiation GO:0032259 methylation GO:0034101 erythrocyte homeostasis GO:0034770 histone H4-K20 methylation GO:0034773 histone H4-K20 trimethylation GO:0034968 histone lysine methylation GO:0035601 protein deacylation GO:0036124 histone H3-K9 trimethylation GO:0040029 regulation of gene expression, epigenetic GO:0043414 macromolecule methylation GO:0045137 development of primary sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046661 male sex differentiation GO:0048232 male gamete generation GO:0048608 reproductive structure development GO:0048821 erythrocyte development GO:0048872 homeostasis of number of cells GO:0051567 histone H3-K9 methylation GO:0051568 histone H3-K4 methylation GO:0060008 Sertoli cell differentiation GO:0060009 Sertoli cell development GO:0061458 reproductive system development GO:0061515 myeloid cell development GO:0061647 histone H3-K9 modification GO:0071514 genetic imprinting GO:0080182 histone H3-K4 trimethylation GO:0097368 establishment of Sertoli cell barrier GO:0098732 macromolecule deacylation
Molecular Function	GO:0004407 histone deacetylase activity GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0019213 deacetylase activity GO:0033558 protein deacetylase activity
Cellular Component	GO:0017053 transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-3214815: HDACs deacetylate histones

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ARID4A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ARID4A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.43; FDR: 0.00979	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ARID4A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.096	0.78
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.488	0.656
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.198	0.834
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.094	0.702
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.075	0.972
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.116	0.965
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.058	0.859
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.245	0.865
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.158	0.922
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.006	0.995
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.047	0.405
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.108	0.105

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ARID4A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	6.8	-3.1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	6.8	-3.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARID4A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARID4A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARID4A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARID4A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ARID4A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ARID4A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ARID4A
Name	AT rich interactive domain 4A (RBP1-like)
Aliases	RBP-1; RBBP1; retinoblastoma-binding protein 1; RBBP-1; ARID domain-containing protein 4A; retinoblastoma bi ......
Chromosomal Location	14q22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ARID4A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ARID4A